パップテストの世界市場：現状分析と予測（2022年～2028年）

世界のパップテスト市場は、子宮頸がん患者の急増、技術開拓、がん検診プログラムの増加により、約11.4％の安定した成長が見込まれています。世界中で子宮頸がんが急増していることが、同市場の成長を促進する主な要因となっています。

当レポートでは、世界のパップテスト市場について調査分析し、市場概要、セグメント別・地域別の市場分析、市場成長への影響因子、市場動向、競合情勢、主要企業プロファイルなどを提供しています。

目次

第1章 市場イントロダクション

第2章 調査手法・前提

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 パップテスト市場に対するCOVID-19の影響

第6章 パップテスト市場収益（2020年～2028年）

第7章 市場洞察：方法別

• 液体ベース
• 従来ベース

第8章 市場洞察：テストタイプ別

• パップスミア
• 一次HPVスクリーニング
• 共同テスト
• HPVのフォローアップ検査

第9章 市場洞察：用途別

• 子宮頸がん検診
• 膣がん検診
• その他

第10章 市場洞察：製品別

• 器具
• 消耗品
• その他

第11章 市場洞察：技術別

• PCR
• その他

第12章 市場洞察：エンドユーザー別

• 研究所
• 診断センター
• 病院・診療所
• その他

第13章 市場洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• 世界のその他の地域

第14章 パップテストの市場力学

• 市場促進要因
• 市場の課題

第15章 パップテストの市場機会

第16章 パップテストの市場動向

第17章 需要サイド・供給サイドの分析

• 需要サイド分析
• 供給サイド分析

第18章 バリューチェーン分析

第19章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第20章 会社概要

• Abbott
• F. Hoffmann-La Roche Ltd.
• BD
• QIAGEN
• Thermo Fisher Scientific Inc.
• HOLOGIC, INC.
• Seegene Inc.
• Arbor Vita Corporation
• Femasys Inc.
• Hospital Equipment Mfg. Co.

第21章 免責事項

The human papillomavirus (HPV) family is made up of 150 or so closely related viruses. The human papillomavirus is divided into different types and numbers. Only particular cell types known as squamous epithelial cells are attracted to the human papillomavirus, and these cells are also the only ones where the virus can thrive. An accurate screening method to ascertain if cervical cells are abnormal or normal is the pap test. Commonly known as a pap smear is a treatment used to check women for cervical cancers. A pap smear can also identify alterations in cervical cells that point to the potential emergence of cancer. People who have abnormal pap test results are encouraged to get a human papillomavirus test to further assess their risk of cervical cancer.

The Pap Test Market is expected to grow at a steady rate of around 11.4% owing to a surge in the cases of cervical cancers, technological developments taking place, and a rise in the number of cancer screening programs. The surge in the prevalence of cervical cancers among the global population is the major factor responsible for thriving the growth of the market. For instance, according to the World Health Organization, 2021, cervical cancer is the world's fourth-most common cancer, with more than 500,000 cases diagnosed every year.

Based on the method, the market is segmented into liquid-based and conventional-based. The liquid-based segment held a dominant share of the market in 2021. The major reason for the growth in this segment is attributed to the advantages that are offered by these methods. Liquid-based methods have been developed to improve the diagnostic reliability of Papanicolaou (Pap) smears. Traditional methods such as conventional pap smears used to have false-negative and false-positive results owing to inefficient sampling and slide preparation, and errors in laboratory detection and interpretation. Liquid-based methods rinse cervical cells in preservatives so that blood and other potentially obscuring material can be easily separated. It also allows for additional testing of the sample, such as HPV, leading to the growth of the pap test market.

On the basis of application, the market is segmented into cervical cancer screening, vaginal cancer screening, and others. The cervical cancer screening category is expected to hold a major market share during the forecast period owing to the rise in the number of cases of cervical cancers worldwide and the rising need for their diagnosis using pap tests. Moreover, rising initiatives and accurate screening programs are now being implemented so that every woman with cervical disease gets the treatment she needs. WHO's global strategy for cervical cancer elimination- endorsed by the World Health Assembly in 2020 - requires 70% of women globally to be screened regularly for cervical disease with a high-performance test, and 90% of those needing it to receive appropriate treatment. Thus, the above-mentioned factors are the significant factor driving the segmental growth during the forecast period.

On the basis of technology, the market is bifurcated into PCR and others. The others held a dominant share of the market in 2021. The others segment consists of colposcopy and ELISA techniques among others. The dominant share is mainly due to the high adoption rate for colposcopy examinations done for the determination of cervical cancers.

For a better understanding of the market adoption of the pap test, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to dominate the global pap test market mainly due to a surge in the cases of cervical cancers, leading to the need for rising awareness related to early screening for cancers, and various initiatives brought in during the forecast period. For instance, in 2020, WHO launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, which outlined three key steps: vaccination, screening, and treatment. Successful implementation of all three reduced more than 40% of new cases of the disease and 5 million related deaths by 2050. Thus, these factors are driving the regional market in the forecast period.

Some of the major players operating in the market include: Abbott, F. Hoffmann-La Roche Ltd., BD, QIAGEN, Thermo Fisher Scientific Inc., HOLOGIC, INC., Seegene Inc., Arbor Vita Corporation, Femasys Inc., Hospital Equipment Mfg. Co., among others.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Pap Test Market
• 2.2. Research Methodology of the Pap Test Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PAP TEST MARKET

6 PAP TEST MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY METHOD

• 7.1. Liquid-based
• 7.2. Conventional-based

8 MARKET INSIGHTS BY TEST TYPE

• 8.1. Pap Smear
• 8.2. Primary HPV Screening
• 8.3. Co-Testing
• 8.4. Follow-Up Test for HPV

9 MARKET INSIGHTS BY APPLICATION

• 9.1. Cervical Cancer Screening
• 9.2. Vaginal Cancer Screening
• 9.3. Others

10 MARKET INSIGHTS BY PRODUCT

• 10.1. Instruments
• 10.2. Consumables
• 10.3. Others

11 MARKET INSIGHTS BY TECHNOLOGY

• 11.1. PCR
• 11.2. Others

12 MARKET INSIGHTS BY END-USER

• 12.1. Research Laboratories
• 12.2. Diagnostic Centers
• 12.3. Hospitals & Clinics
• 12.4. Others

13 MARKET INSIGHTS BY REGION

• 13.1. North America
  • 13.1.1. U.S.
  • 13.1.2. Canada
  • 13.1.3. Rest of North America
• 13.2. Europe
  • 13.2.1. Germany
  • 13.2.2. U.K.
  • 13.2.3. France
  • 13.2.4. Italy
  • 13.2.5. Spain
  • 13.2.6. Rest of Europe
• 13.3. Asia-Pacific
  • 13.3.1. China
  • 13.3.2. Japan
  • 13.3.3. India
  • 13.3.4. Rest of Asia-Pacific
• 13.4. Rest of World

14 PAP TEST MARKET DYNAMICS

• 14.1. Market Drivers
• 14.2. Market Challenges

15 PAP TEST MARKET OPPORTUNITIES

16 PAP TEST MARKET TRENDS

17 DEMAND AND SUPPLY-SIDE ANALYSIS

• 17.1. Demand Side Analysis
• 17.2. Supply Side Analysis

18 VALUE CHAIN ANALYSIS

19 COMPETITIVE SCENARIO

• 19.1. Competitive Landscape
  • 19.1.1. Porters Fiver Forces Analysis

20 COMPANY PROFILED

• 20.1. Abbott
• 20.2. F. Hoffmann-La Roche Ltd.
• 20.3. BD
• 20.4. QIAGEN
• 20.5. Thermo Fisher Scientific Inc.
• 20.6. HOLOGIC, INC.
• 20.7. Seegene Inc.
• 20.8. Arbor Vita Corporation
• 20.9. Femasys Inc.
• 20.10. Hospital Equipment Mfg. Co.

21 DISCLAIMER